Paraplatin and Necrosis - a phase IV clinical study of FDA data

Summary:

Necrosis is reported as a side effect among people who take Paraplatin (carboplatin), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Taxol, and have Tongue neoplasm malignant stage unspecified.

The phase IV clinical study analyzes which people have Necrosis when taking Paraplatin. It is created by eHealthMe based on reports of 12,385 people who have side effects when taking Paraplatin from the FDA, and is updated regularly.

What is Paraplatin?

Paraplatin has active ingredients of carboplatin. eHealthMe is studying from 12,392 Paraplatin users. Check the latest studies of Paraplatin.

What is Necrosis?

Necrosis (the death of body tissue) is found to be associated with 748 drugs and 970 conditions by eHealthMe. Check the latest studies of Necrosis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

12,385 people reported to have side effects when taking Paraplatin.
Among them, 25 people (0.2%) have Necrosis.

Among these 25 people:

How long have people been on Paraplatin when they have Necrosis? *

What is the gender of people who have Necrosis when taking Paraplatin? *

female: 64 %
male: 36 %

What is the age of people who have Necrosis when taking Paraplatin? *

What are other drugs people take besides Paraplatin? *

What are other side effects people have besides Necrosis? *

Fever: 6 people, 24.00%
Acute Circulatory Failure (shock): 4 people, 16.00%
Thrombocytopenia (decrease of platelets in blood): 3 people, 12.00%
Hypotension (abnormally low blood pressure): 3 people, 12.00%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 3 people, 12.00%
Anorexia (eating disorder characterized by immoderate food restriction and irrational fear of gaining weight): 2 people, 8.00%
Chest Pain: 2 people, 8.00%
Hyperuricaemia (level of uric acid in the blood that is abnormally high): 2 people, 8.00%
Hypersensitivity: 2 people, 8.00%
Hyperkalemia (damage to or disease of the kidney): 2 people, 8.00%

What are the existing conditions these people have? *

Tongue Neoplasm Malignant Stage Unspecified: 3 people, 12.00%
Pain: 1 person, 4.00%
Ovarian Cancer (cancer of ovary): 1 person, 4.00%
Nausea And Vomiting: 1 person, 4.00%
Nausea (feeling of having an urge to vomit): 1 person, 4.00%
Multiple Myeloma (cancer of the plasma cells): 1 person, 4.00%
Lung Neoplasm Malignant (cancer tumour of lung): 1 person, 4.00%
Lung Cancer - Non-Small Cell (lung cancer): 1 person, 4.00%
Langerhans' Cell Granulomatosis: 1 person, 4.00%
Insomnia (sleeplessness): 1 person, 4.00%

* Approximation only. Some reports may have incomplete information.

Do you take Paraplatin and have Necrosis?

- Check whether Necrosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Paraplatin:

Paraplatin (12,392 reports)

Necrosis treatments and more:

Necrosis (8,274 reports)

Browse all side effects of Paraplatin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Necrosis:

Necrosis (748 drugs)

Browse all the conditions that are associated with Necrosis:

Necrosis (970 conditions)

Related publications that referenced our studies

Zakaria S, Lu KY, Nussenblatt V, Browner I, "Atrial flutter associated with carboplatin administration", Annals of Pharmacotherapy, 2011 Nov .
Zakaria S, Lu KY, Nussenblatt V, Browner I, "Atrial flutter associated with carboplatin administration", Annals of Pharmacotherapy, 2011 Nov .

How the study uses the data?

The study uses data from the FDA. It is based on carboplatin (the active ingredients of Paraplatin) and Paraplatin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.